Ignite Creation Date:
2025-12-24 @ 4:14 PM
Ignite Modification Date:
2026-02-02 @ 12:21 AM
Study NCT ID:
NCT04476966
Status:
COMPLETED
Last Update Posted:
2020-07-21
First Post:
2020-07-15
Is Gene Therapy:
True
Has Adverse Events:
False
Brief Title:
Bioequivalence Study of Mirabegron From Bladogra 25 mg Extended Release Tablets (Multi-Apex for Pharmaceutical Industries, Egypt) Versus Myrbetriq 25 mg Extended Release Tablets (Marketed by Astellas Pharma US, Inc, Product of Japan)
Sponsor:
Genuine Research Center, Egypt
Organization:
Organization Data
Organization:
Class:
INDUSTRY
Study ID:
GRC/1/19/828
Study Type:
None
Study Domain:
None
Study Link:
None
Lead Sponsor:
Lead Sponsor Class:
INDUSTRY
Responsible Party:
Responsible Party Title:
Responsible Party Type:
SPONSOR
Responsible Party Affiliation:
Old Name:
None
Old Organization:
None
Collaborators
Collaborators
| Name | Class | View |
|---|---|---|
| None | INDUSTRY | View |